A history of cannabis use is associated with persistent lower fasting insulin levels in obese subjects, according to new data published in The Journal of Diabetes. A new product using bio-encapsulation hopes to streamline the absorption of cannabinoids to enhance this effect.
Canadian researchers assessed the relationship between cannabis consumption, fasting insulin levels and insulin resistance in a nationally representative sample of over 129,000 adults in the new study.
They reported in June that both current and past cannabis use was associated with significant and persistent changes in insulin levels in obese subjects compared to non-users. However, these changes were only evident in overweight subjects.
In a related development, California-based Liposome Formulations Inc. released four new medical cannabis formulations last December, one of which is for diabetic patients.
Benefits persist for over a decade
“We found that lifetime marijuana use is significantly associated with lower fasting insulin and HOMA-IR (a measure of insulin resistance) in obese individuals,” the Canadian study authors concluded.
“We also found that, a long time (> 10 years) after cessation, former users showed significant lower levels of fasting insulin and HOMA-IR scores than did never users, independent of their frequency of use in the past.”
The study is encouraging for Liposome Formulations, an FDA, NSF and CGMP Registered Pharmaceutical Company and worldwide leader in patented Liposomal Technology for enhanced bioavailability. It also has drugs for osteoarthritis in clinical trials with the FDA.
Focus on enhanced absorption
The company’s new product lines, featuring mainly Cannabidiol (CBD), is designed for extremely rapid absorption into the patients’ blood stream. It reports that bio-encapsulation of the cannabis molecule can absorb up to 75 percent more medicine into the body than typical applications like oral delivery and slower elimination than inhaled delivery.
This allows for an extended treatment with rapid onset. Simply put, the Bio-enhanced product line saves the patient money through a more complete absorption rate with longer lasting results.
- The THCV diabetic/weight loss capsule uses THCV and its acidic parent THCVa, among the rarest commercial cannabinoids in the world. Liposome produces this incredible yet scarce molecule in unlimited quantities through industrial hemp cultivation, at its MCRCM research and conservation facility in Marin County, California.
- Another product is a 5ml foil packet with 25mg Cannabinol and Phosphatidylcholine. This is a tincture product taken orally and comes in a ten-pack box.
- The Lipiquel line is a pharmaceutical grade I.V. product, using pure CBD, to reduce the unpleasant effects caused by accidently consuming too much psychoactive cannabis. A first responder version of this medicine, to reduce cannabis-related hospital visits, is also underway, with clinical trials soon to be announced.
- Liposome’s next product is an arthritis topical cream featuring CBD and Phosphatidylcholine. This is an extremely fast acting topical to aid in pain management, by reducing inflammation and pain associated with osteoarthritis.
Longtime Marin County resident George Bianchini, founder of the medical cannabis company Medi-Cone, said he and research partner Ed Rosenthal accidentally stumbled upon the strain of cannabis that produces high amounts of THCV. Steep Hill Labs in Oakland tested the cultivar and told him that the strain was producing an unusually high ratio of THCv — about 3.5 percent.